Short Interest in Valneva SE (NASDAQ:VALN) Declines By 84.2%

Valneva SE (NASDAQ:VALN) was the recipient of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 5,800 shares, a drop of 84.2% from the February 13th total of 36,700 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 59,500 shares, the short-interest ratio is presently 0.1 days.

Valneva Stock Down 0.4 %

NASDAQ VALN opened at $7.03 on Thursday. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average of $6.02 and a two-hundred day moving average of $5.62. The firm has a market capitalization of $571.26 million, a price-to-earnings ratio of -54.08 and a beta of 1.93. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN grew its stake in shares of Valneva SE (NASDAQ:VALN) by 14.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 246,766 shares of the company’s stock after purchasing an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent quarter. Institutional investors own 11.39% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Valneva in a research report on Friday, February 28th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.